Novonesis (NSIS) AGM 2025 summary

Opening remarks and agenda

• Meeting chaired by Anders Ørjan Jensen; agenda covered financial review, elections, remuneration, auditor appointment, and shareholder proposals.

• 88% of total votes and 76% of share capital were represented; most votes were cast in advance.

Financial performance review

• 2024 organic sales growth was 8%, comprising 6% volume growth and 2% pricing; revenue totaled EUR 3,946 million.

• Adjusted EBITDA margin was 36.1%; free cash flow excluding acquisitions was EUR 667.5 million, and operating cash flow was EUR 1 billion.

• Year-end market capitalization was ~EUR 26 billion; share price rose 11% while total shareholder return was -12%.

• Growth was strong across Food & Health and Planetary Health Biosolutions, with all business areas contributing and emerging markets especially strong.

Board and executive committee updates

• Cees de Jong was re-elected Chair and Heine Dalsgaard re-elected and elected Vice Chair; Monila Kothari joined the Board as a new director.

• Lise Kaae, Kasim Kutay, Kevin Lane, Morten Otto Alexander Sommer, and Kim Stratton were re-elected; employee representatives were also elected.

• Board committee appointments were confirmed; the interim Integration Committee was dissolved, with integration oversight moving to the Board.

• Board remuneration increased 3.5% to EUR 1.8 million; executive management remuneration was EUR 9.7 million, including a one-time integration bonus.